Two meningococcal B vaccines receive FDA 'breakthrough therapy' designation.
Eva M
EM
Riedmann
D000293:Adolescent; D000328:Adult; D002648:Child; D017277:Drug Approval; D006801:Humans; D008589:Meningococcal Infections / Q000453:epidemiology / Q000276:immunology / Q000382:microbiology* / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D014481:United States; D014486:United States Food and Drug Administration; D055815:Young Adult
D022401:Meningococcal Vaccines